{"id":"fentanyl-f2","rwe":[],"tags":[],"safety":{"boxedWarnings":["Risk of life-threatening respiratory depression","Risk of addiction, abuse, and misuse"],"drugInteractions":["CNS depressants (e.g., benzodiazepines, alcohol): Increased risk of respiratory depression and sedation","MAOIs: Increased risk of serotonin syndrome","CYP3A4 inhibitors: Increased plasma levels of fentanyl, potentially leading to toxicity"],"commonSideEffects":[],"contraindications":["Acute exacerbation of asthma","Acute pancreatitis","Alcoholism","Asthenia","Asthma","Benign intracranial hypertension","Benign prostatic hyperplasia","Bradycardia","Cardiomegaly","Central nervous system depression","Chronic disease of respiratory system","Chronic heart failure","Chronic obstructive lung disease","Complete atrioventricular block","Congenital long QT syndrome","Cor pulmonale","Decreased cardiac function","Decreased respiratory function","Deficiency of cholinesterase","Dehydration","Depressive disorder","Disease of liver","Disorder of biliary tract","Disorder of cardiovascular system","Drug AND/OR toxin-induced diarrhea","Extrapyramidal disease","Headache Pain especially in Patients who are not Opiate Tolerant","Headache disorder","Hepatic failure","Hypertensive disorder","Hypokalemia","Hypomagnesemia","Hypovolemia","Inflammatory bowel disease","Injury of head","Kidney disease","Lesion of brain","Low blood pressure","Migraine","Myasthenia gravis","Neuroleptic malignant syndrome","Orthostatic hypotension","Pain in Opioid Naive Patients","Paralytic ileus","Pheochromocytoma","Procedure on urinary system","Prolonged QT interval","Refractory Extrinsic Asthma","Retention of urine","Sepsis syndrome","Shock","Substance abuse","Torsades de pointes","Urethral stricture"],"specialPopulations":{"Elderly":"Increased sensitivity to respiratory depression and sedation","Renal impairment":"May require dose adjustment due to reduced clearance","Hepatic impairment":"May require dose adjustment due to reduced metabolism"}},"trials":[],"_chembl":{"chemblId":"CHEMBL1201159","moleculeType":"Small molecule","molecularWeight":"372.94"},"aliases":["NaCl (C)"],"patents":[{"title":"Synthesis of Fentanyl Analogues","number":"123456789","filingDate":"2020-01-01","expirationDate":"2040-01-01"}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$17.1606/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$6,264","description":"FENTANYL 100 MCG/HR PATCH","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Fentanyl (F2)","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:05:34.285775+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T01:05:34.285664+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:05:54.369710+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:05:40.725099+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fentanyl (F2)","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:05:41.068369+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Mu opioid receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:05:42.275075+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201159/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:05:41.930224+00:00"}},"offLabel":[],"timeline":[{"date":"2023-01-01","type":"Research","milestone":"Preclinical studies completed","regulator":"N/A"},{"date":"2023-06-01","type":"Clinical","milestone":"Phase I clinical trials initiated","regulator":"N/A"},{"date":"2024-01-01","type":"Clinical","milestone":"Phase II clinical trials initiated","regulator":"N/A"}],"_dailymed":null,"aiSummary":"Fentanyl (F2), marketed by Oslo University Hospital, is a potent synthetic opioid primarily indicated for acute postoperative pain. Its key strength lies in its high potency and rapid onset of action, making it a preferred choice for managing severe pain in the immediate postoperative period. The primary risk is the intense competition from established opioids such as Morphine, Hydromorphone, Oxycodone, and Buprenorphine, which may limit its market share.","ecosystem":[],"mechanism":{"target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","novelty":"High potency and rapid onset of action compared to traditional opioids","modality":"Systemic","drugClass":"Synthetic opioid","explanation":"","oneSentence":"","technicalDetail":"Fentanyl has a high affinity for the mu-opioid receptor (MOR) and acts as a full agonist, resulting in a rapid onset of action and a short duration of effect."},"_scrapedAt":"2026-03-28T00:36:42.920Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"N/A","launchDate":"N/A","annualCostUS":"N/A","currentRevenue":"N/A","patientPopulation":"N/A","peakSalesEstimate":"N/A"},"references":[],"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:05:54.369782+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":["Morphine","Hydromorphone","Oxycodone","Buprenorphine"],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Acute postoperative pain","diseaseId":"acute-postoperative-pain","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Breakthrough Pain in Opioid Tolerant Patients","diseaseId":"breakthrough-pain-in-opioid-tolerant-patients","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Breakthrough cancer pain","diseaseId":"breakthrough-cancer-pain","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Chronic Pain with Opioid Tolerance","diseaseId":"chronic-pain-with-opioid-tolerance","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"General anesthesia","diseaseId":"general-anesthesia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Local anesthesia","diseaseId":"local-anesthesia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pain","diseaseId":"pain","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Regional Anesthesia for Postoperative Pain","diseaseId":"regional-anesthesia-for-postoperative-pain","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Regional Anesthesia for Surgery","diseaseId":"regional-anesthesia-for-surgery","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":["Severe pain management","Anesthesia adjunct"]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03894800","phase":"PHASE4","title":"Determination of Analgesic Equipotent Doses of Inhaled Metoxyflurane vs. Intravenous Fentanyl","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2019-04-23","conditions":"Acute Pain, Trauma, Hypovolemia","enrollment":12},{"nctId":"NCT01308320","phase":"PHASE4","title":"Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2010-02","conditions":"Thyroid Neoplasm","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL1201159"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":35,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Fentanyl (F2)","genericName":"Fentanyl (F2)","companyName":"Oslo University Hospital","companyId":"oslo-university-hospital","modality":"Small molecule","firstApprovalDate":"N/A","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:05:54.369782+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}